Workflow
第十一批国家组织药品集采报量正式启动
证券时报·2025-08-07 04:39

Core Viewpoint - The article discusses the recent announcement by the National Organization for Drug Procurement regarding the 11th batch of centralized drug procurement, highlighting the new reporting requirements and rules for medical institutions [1]. Group 1: Reporting Characteristics - Medical institutions can report demand by brand name or by generic name, allowing for greater flexibility in participation [1]. - Accurate reporting is emphasized, with a requirement that each institution's reported annual demand for each product should not be less than 80% of the average usage for 2023-2024 [1]. - The reporting system is designed to align with policies on essential medicines and pediatric medications, allowing institutions to report based on actual needs if certain conditions are met [1]. Group 2: Brand Selection and Reporting Process - The selection of brands available for reporting is based on prior submissions from companies that have provided relevant drug information [3]. - Institutions can choose to report demand either by product type or by brand, with no limit on the number of brands selected [4]. - The reporting system automatically calculates whether the reported demand meets the historical procurement volume requirement of 80% [5]. Group 3: Special Considerations - Institutions facing challenges in meeting the 80% requirement due to special circumstances can submit explanations for reduced reporting [6]. - For unapproved specifications and essential medicines, institutions can determine their own reporting ratios based on clinical needs [7]. - Special considerations are made for pediatric formulations, allowing institutions to report based on actual needs if certain formulations have not passed consistency evaluations [8]. Group 4: Participation and Compliance - The procurement process allows for participation from private medical institutions and retail pharmacies, promoting access to quality medicines [12]. - Institutions are encouraged to prioritize the use of selected drugs while still having the option to procure non-selected products for remaining needs [10][11]. - The article outlines the process for new users to register and for existing users to recover their accounts [13].